07:13 AM EDT, 03/21/2025 (MT Newswires) -- Telix Pharmaceuticals ( TLX ) said Friday that the US Food and Drug Administration has approved its new drug application for Gozellix, a PSMA-PET imaging agent for prostate cancer.

Gozellix is indicated for PET scanning of PSMA positive lesions in men having prostate cancer which may have metastasized and are eligible for initial definitive therapy, and those with suspected recurrence of the disease, the company said.

Telix shares were up 3.8% in recent premarket trading.